Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,733 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03418922 | A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma | completed | Phase 1 | 30 | Eisai Co., Ltd.INDUSTRY | 1 | Jun 20, 2024 | clinicaltrials |
| NCT02834052 | Pembrolizumab + Poly-ICLC in MRP Colon Cancer | completed | Phase 1 / Phase 2 | 42 | Asha NayakOTHER | 1 | Jun 7, 2024 | clinicaltrials |
| NCT02318329 |
| Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors |
| completed |
| Phase 1 |
| 79 |
| Five Prime Therapeutics, Inc.INDUSTRY |
| 3 |
| Jun 4, 2024 |
| clinicaltrials |
| NCT04357587 | Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer | completed | Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT03720678 | A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies | completed | Phase 1 | 44 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT04400383 | Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors | completed | Phase 1 | 62 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | May 24, 2024 | clinicaltrials |
| NCT03256344 | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | completed | Phase 1 | 36 | AmgenINDUSTRY | 6 | May 14, 2024 | clinicaltrials |
| NCT01851369 | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | May 8, 2024 | clinicaltrials |
| NCT04835896 | Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer | completed | Phase 1 / Phase 2 | 49 | Yonsei UniversityOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT01832116 | 89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients(MMOT) | completed | Phase 1 | 11 | University Medical Center GroningenOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT02760199 | 89Zr-AMG211 PET Imaging Study | completed | Phase 1 | 9 | University Medical Center GroningenOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT04216251 | PRevention Using EPA Against coloREctal Cancer(PREPARE) | completed | Phase 1 / Phase 2 | 81 | Massachusetts General HospitalOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT00575562 | Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer | completed | Phase 1 | 42 | Kyowa Kirin, Inc.INDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT01447732 | Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 71 | Kyowa Kirin Co., Ltd.INDUSTRY | 0 | Apr 29, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT02705105 | Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 114 | Kyowa Kirin, Inc.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04444167 | A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 59 | AkesoINDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT03330561 | PRS-343 in HER2-Positive Solid Tumors | completed | Phase 1 | 85 | Pieris Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03650348 | PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | completed | Phase 1 | 41 | Pieris Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT05518201 | Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old | completed | Phase 1 | 90 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT01972373 | Visualization of Rectal Cancer During Endoscopy, Using a Fluorescent Tracer(RAPIDO-TRACT) | completed | Phase 1 | 30 | University Medical Center GroningenOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT02129933 | VEGF-targeted Fluorescence Near-Infrared (NIR) Endoscopy in (Pre)Malignant Esophageal Lesions(VICE) | completed | Phase 1 | 14 | University Medical Center GroningenOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT03205501 | Molecular Fluorescence Endoscopy of (Pre)Malignant Esophageal Lesions(EAGLE) | completed | Phase 1 | 15 | University Medical Center GroningenOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT04638036 | Fluorescence Molecular Endoscopy and Molecular Fluorescence-guided Surgery in Locally Advanced Rectal Cancer(TRACT-II) | completed | Phase 1 | 11 | University Medical Center GroningenOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | completed | Phase 1 | 146 | Blueprint Medicines CorporationINDUSTRY | 12 | Apr 12, 2024 | clinicaltrials |
| NCT03317119 | Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery | completed | Phase 1 | 26 | City of Hope Medical CenterOTHER | 1 | Apr 8, 2024 | clinicaltrials |
| NCT03490669 | Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors | completed | Phase 1 | 41 | AstraZenecaINDUSTRY | 3 | Apr 5, 2024 | clinicaltrials |
| NCT01761240 | Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Mar 29, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT02273362 | Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver | completed | Phase 1 / Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Mar 26, 2024 | clinicaltrials |
| NCT02735239 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer | completed | Phase 1 / Phase 2 | 73 | Ludwig Institute for Cancer ResearchOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT03373188 | VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer | completed | Phase 1 | 10 | Emory UniversityOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT04431258 | ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study(PanC-ASAP) | completed | Phase 1 / Phase 2 | 150 | Ability Pharmaceuticals SLINDUSTRY | 4 | Mar 18, 2024 | clinicaltrials |
| NCT03619681 | Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer | completed | Phase 1 | 63 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04834778 | A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) | completed | Phase 1 | 23 | HiberCell, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT00019006 | Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00019630 | Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00020267 | Vaccine Therapy in Treating Patients With Metastatic Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03343301 | A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer(FIGHT) | completed | Phase 1 | 12 | Five Prime Therapeutics, Inc.INDUSTRY | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03751761 | GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study | completed | Phase 1 / Phase 2 | 58 | Asan Medical CenterOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06278493 | A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 34 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT02168140 | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | completed | Phase 1 | 16 | Wake Forest University Health SciencesOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT01959139 | S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 126 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 9, 2024 | clinicaltrials |
| NCT03893695 | Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) | completed | Phase 1 / Phase 2 | 20 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT04074343 | TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma | completed | Phase 1 | 20 | University of California, IrvineOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT03255070 | A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01) | completed | Phase 1 | 106 | Ambrx, Inc.INDUSTRY | 2 | Feb 1, 2024 | clinicaltrials |
| NCT05074472 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | completed | Phase 1 / Phase 2 | 35 | ZielBio, Inc.INDUSTRY | 1 | Jan 29, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jun 20, 2024source: clinicaltrials